Estrogen Receptors alpha and beta in Ovarian Cancer: Expression Level and Prognosis

The quantitative immunofluorescence assay of serous ovarian cancer tissue for the expression of estrogen receptors (ERα and ERβ) revealed a higher expression level of ERβ in comparison with ERα in all surgical tumor samples investigated. Significant differences in the expression level of the markers...

Full description

Saved in:
Bibliographic Details
Published inDoklady. Biochemistry and biophysics Vol. 482; no. 1; pp. 249 - 251
Main Authors Bogush, T. A., Basharina, A. A., Bogush, E. A., Ryabinina, O. M., Tjulandina, A. S., Tjulandin, S. A.
Format Journal Article
LanguageEnglish
Published Moscow Pleiades Publishing 01.09.2018
Springer Nature B.V
Subjects
Biochemistry
Biological and Medical Physics
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biophysics
Chemotherapy
Disease-Free Survival
Estrogen Receptor alpha - metabolism
Estrogen Receptor beta - metabolism
Estrogen receptors
Female
Fluorescent Antibody Technique
Humans
Immunofluorescence
Life Sciences
Medical prognosis
Molecular Biology
Ovarian cancer
Ovarian carcinoma
Ovarian Neoplasms - diagnosis
Platinum
Prognosis
Transcriptome
Online AccessGet full text

Cover

More Information
Summary:The quantitative immunofluorescence assay of serous ovarian cancer tissue for the expression of estrogen receptors (ERα and ERβ) revealed a higher expression level of ERβ in comparison with ERα in all surgical tumor samples investigated. Significant differences in the expression level of the markers were detected “from tumor to tumor.” A high expression level of both ERα (≥ 25%) and ERβ (≥ 44%) in the tumor predicts a significantly longer progression-free survival time ( p < 0.01) in the patients after the first line of platinum and taxane-based adjuvant chemotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1607-6729
1608-3091
DOI:10.1134/S1607672918050058